✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Sudarshan Pharma Industries Ltd.

SUDARSHAN

Market Cap
₹985 Cr.
P/E
42.25

Sudarshan Pharma Industries Ltd.

  • Sudarshan Pharma (I)
  • Wanbury
  • Bajaj Healthcare

FAQs on Sudarshan Pharma Industries Ltd. Shareprice

Sudarshan Pharma (I) has given better returns compared to its competitors.
Sudarshan Pharma (I) has grown at ~63.68% over the last 3yrs while peers have grown at a median rate of 28.24%

Yes, Sudarshan Pharma (I) is expensive.
Latest PE of Sudarshan Pharma (I) is 42.25, while 3 year average PE is 41.59.
Also latest EV/EBITDA of Sudarshan Pharma (I) is 24.7 while 3yr average is 18.26.

View FAQ's On Business

Growth Table

  • Sudarshan Pharma Industries Ltd.
  • Wanbury
  • Bajaj Healthcare

Balance Sheet

  • Sudarshan Pharma Industries Ltd.
  • Wanbury
  • Bajaj Healthcare

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Sudarshan Pharma Industries Ltd.
  • Wanbury
  • Bajaj Healthcare

Cash Flow

  • Sudarshan Pharma Industries Ltd.
  • Wanbury
  • Bajaj Healthcare

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Sudarshan Pharma Industries Ltd.
  • Wanbury
  • Bajaj Healthcare

Quarterly Results

  • Sudarshan Pharma Industries Ltd.
  • Wanbury
  • Bajaj Healthcare

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Sudarshan Pharma Industries Ltd. Financials

Balance sheet of Sudarshan Pharma (I) is moderately strong, But short term working capital might become an issue for this company.

Yes, The net debt of Sudarshan Pharma (I) is increasing.
Latest net debt of Sudarshan Pharma (I) is ₹282 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹170 Crs.

Yes, profit is increasing.
The profit of Sudarshan Pharma (I) is ₹23.37 Crs for TTM, ₹15.96 Crs for Mar 2025 and ₹11.46 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Sudarshan Pharma (I) latest dividend payout ratio is 10.26% and 3yr average dividend payout ratio is 10.26%

Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech